ライフサイエンスコーパス: FDA

1 FDA drug review times declined from more than 3 years in

2 FDA guidance recommends conducting in vitro skin permeat

3 FDA or EUCAST breakpoints should be applied to interpret

4 FDA-approved assays for fungal diagnosis are generally f

5 FDA-approved enzalutamide is commonly prescribed for CRP

6 FDA-approved RAF inhibitors poorly inhibit BRAF dimers,

7 Here, we screen a library of 2024 FDA-approved drugs or drug candidates, revealing UMI-77

8 We used HeLa cells and screened 231 FDA-approved oncology and natural substance drugs includ

9 e like cell lines treated with a panel of 26 FDA-approved KIs and classify their effects on subcellul

10 d screened for synthetic lethality with 3009 FDA-approved compounds.

11 The study cohort comprised 57 FDA-approved vaccines.

12 utics are becoming more common, with over 60 FDA-approved peptides for clinical use.

13 ity at 65% and 66%, compared to 74% and 72% (FDA) and 87% and 89% (CLSI) by HardyDisks and MASTDISCS,

14 publicly available databases, we curated 883 FDA approved or investigational stage small molecule can

15 A FDA-approved drug high-throughput viability assay shows

16 Here, we found that olaparib, a FDA-approved PARP inhibitor, could enhance the cytotoxic

17 still, a long way should be paved to achieve FDA approval for most of the proposed products.

18 ned with the US Food and Drug Administation (FDA)-approved drugs Orkambi (lumacaftor/ivacaftor) and T

19 following U.S. Food and Drug Administration (FDA) and International Standards Organization (ISO) stan

20 United States Food and Drug Administration (FDA) and other regulatory agencies about developing crit

21 7-28, 2018 the Food and Drug Administration (FDA) and the Critical Path Institute's Transplant Therap

22 ue-agnostic US Food and Drug Administration (FDA) approval for adult and pediatric patients with Trk-

23 hough the U.S. Food and Drug Administration (FDA) approved for transport and culture of enteric bacte

24 ts that are US Food and Drug Administration (FDA) approved in the upfront and the recurrent setting.

25 ed by the U.S. Food and Drug Administration (FDA) as "breakthrough therapies" for posttraumatic stres

26 oved by the US Food and Drug Administration (FDA) between 2009 and 2018 to estimate the research and

27 t and the U.S. Food and Drug Administration (FDA) Bioanalytical Method Validation Guidance for Indust

28 In 2016, the Food and Drug Administration (FDA) changed labeling regarding metformin contraindicati

29 successful US Food and Drug Administration (FDA) de novo authorization of an example, the first auto

30 ch access, the Food and Drug Administration (FDA) developed a model drug facts label for such sales t

31 available U.S. Food and Drug Administration (FDA) drug reviews, all reported CVD events across latter

32 Although U.S. Food and Drug Administration (FDA) drugs are approved for the treatment of influenza i

33 While Food and Drug Administration (FDA) emergency use authorization (EUA) is required for c

34 oV-2 under the Food and Drug Administration (FDA) Emergency Use Authorization (EUA) pathway.

35 oved by the US Food and Drug Administration (FDA) for human use.

36 ed by the U.S. Food and Drug Administration (FDA) for in vitro diagnostic use, assays for the detecti

37 red by the U.S.Food and Drug Administration (FDA) for new approvals of opioid analgesics.

38 page of the US Food and Drug Administration (FDA) for pregnancy exposure reports.

39 oved by the US Food and Drug Administration (FDA) for r/r ALL (CD19CAR T-cell approval is restricted

40 The U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) statu

41 The US Food and Drug Administration (FDA) has led the Sequencing Quality Control (SEQC) proje

42 oved by the US Food and Drug Administration (FDA) in 1985.

43 xamined by the Food and Drug Administration (FDA) in this investigation have been found to contain VE

44 nge for the US Food and Drug Administration (FDA) is to achieve an appropriate balance between rigoro

45 The US Food and Drug Administration (FDA) issued a new proposed rule in 2019 (84.FR.6204) for

46 hrough to U.S. Food and Drug Administration (FDA) licensure was tracked.

47 waters of the Food and Drug Administration (FDA) new-drug application (NDA) process that ultimately

48 Neither the Food and Drug Administration (FDA) nor the Clinical and Laboratory Standards Institute

49 oved by the US Food and Drug Administration (FDA) on June 29, 2020.

50 that the U.S. Food and Drug Administration (FDA) plays in its regulation of neuroimplantable technol

51 ding to the US Food and Drug Administration (FDA) snapshot analysis.

52 time following Food and Drug Administration (FDA) TCS bans.

53 l (ODP) of the Food and Drug Administration (FDA) to determine whether a relationship exists between

54 tted to the US Food and Drug Administration (FDA) were analyzed to map the safety profile of epiderma

55 e (CLSI), U.S. Food and Drug Administration (FDA), and European Committee on Antimicrobial Susceptibi

56 , 16 by the US Food and Drug Administration (FDA), and ten by the Japan Pharmaceuticals and Medical D

57 s, such as the Food and Drug Administration (FDA), to secure safe use of deep learning methods.

58 related to the Food and Drug Administration (FDA)-approved drug fluoxetine-which also targets 2C-but

59 ilotinib, a US Food and Drug Administration (FDA)-approved drug for leukemia, indicates improvement i

60 this study, an Food and Drug Administration (FDA)-approved drug, diflunisal, was found to competitive

61 Anakinra, a US Food and Drug Administration (FDA)-approved IL-1R antagonist; or parthenolide, a caspa

62 e currently no Food and Drug Administration (FDA)-approved pharmacotherapies.

63 nical-stage or Food and Drug Administration (FDA)-approved small molecules to identify candidate ther

64 lchicine, a US Food and Drug Administration (FDA)-approved treatment for inflammatory disorders that

65 e currently no Food and Drug Administration (FDA)-approved treatments.

66 Food and Drug Administration (FDA)-approved vaccine labels.

67 CE To date, no Food and Drug Administration (FDA)-approved vaccines are available to combat hemorrhag

68 ion, but no US Food and Drug Administration (FDA)-cleared assays for detection at these sites existed

69 cleared by the Food and Drug Administration (FDA).

70 United States Food and Drug Administration (FDA).

71 nded by the US Food and Drug Administration (FDA).

72 t-to-treat; US Food and Drug Administration [FDA] snapshot) at week 48; participant satisfaction was

73 we have compiled the structural data for all FDA Green Book drugs approved through the end of 2019.

74 rapeutic targets, accounting for ~35% of all FDA-approved drugs.

75 ed in the saliva specimen using an alternate FDA EUA assay.

76 An FDA-approved inhibitor of GTP synthesis potentiates the

77 isual outcomes comparable to aflibercept (an FDA-approved VEGF-A antagonist).

78 RUNX1 inhibitor Ro5-3335, aflibercept-an FDA-approved vascular endothelial growth factor (VEGF) i

79 Importantly, recombinant G-CSF exists as an FDA-approved medication which may facilitate rapid clini

80 tial utility of beta-caryophyllene (BCP), an FDA-approved food additive for the treatment of CUD.

81 p21/HIF-1alpha/VEGF-A signaling with Bex, an FDA-approved drug, may increase the DTX chemo-sensitivit

82 the key structural elements of darunavir, an FDA-approved drug for the treatment of HIV/AIDS.

83 e used digital breast tomosynthesis (DBT) an FDA approved tomographic X-ray breast imaging method as

84 r the selection of sunscreen products for an FDA-sponsored proof-of-concept maximal usage clinical tr

85 Fingolimod (FTY720), an FDA-approved immunomodulatory drug for treating multiple

86 o/vivo-Clinical Data Mining), to identify an FDA-approved drug suitable for use as an effective analg

87 nhibitor, in combination with Primaxin is an FDA-approved (Recarbrio) treatment for serious and antib

88 Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with dem

89 Ivermectin is an FDA-approved broad-spectrum antiparasitic drug that also

90 Moreover, since fenofibrate is an FDA-approved drug that has an excellent safety profile,

91 Disulfiram (DSF) is an FDA-approved drug that has been repurposed for cancer tr

92 Our results demonstrate that ivermectin, an FDA-approved antiparasitic agent, is effective at inhibi

93 These data reveal that lumefantrine, an FDA-approved drug, represents a potential GBM therapeuti

94 In addition, nilotinib, an FDA-approved kinase inhibitor that preferentially binds

95 Purple corn offers an FDA and EFSA-approved economical source of anthocyanin-b

96 liver cancer sensitivity to palbociclib, an FDA-approved CDK4 inhibitor, which was effective in trea

97 Of interest, pirfenidone (Pf), an FDA approved anti-fibrotic drug to treat idiopathic pulm

98 Spironolactone (SP), an FDA approved aldosterone antagonist, triggers the protea

99 ffect that can be rescued by tigecycline, an FDA-approved drug that specifically suppresses mitochond

100 Here, we use an FDA-approved non-toxic drug, benzalkonium chloride (BC),

101 irmed in human psoriasis using vorapaxar, an FDA-approved PAR1 antagonist, on explanted lesional skin

102 , SVM, and functional discriminant analysis (FDA) models indicate that SVM is the most accurate for p

103 ral laws and FDA regulations (1962-2018) and FDA databases of approved new drugs (1984-2018), generic

104 n in the majority of clinical candidates and FDA approved covalent therapies.

105 tive SRC inhibitor has been challenging, and FDA-approved SRC inhibitors, dasatinib and bosutinib, ar

106 urveillance and allow future development and FDA regulatory approval of modernized AST to guide treat

107 e antibiotic ciprofloxacin hydrochloride and FDA-approved polymers are fabricated.

108 evidence included principal federal laws and FDA regulations (1962-2018) and FDA databases of approve

109 the best algorithm for wildfire mapping, and FDA is the most accurate model for predicting snow avala

110 antibiotics, vancomycin and fidaxomicin, are FDA-approved for the treatment of C. difficile infection

111 ostic assays face challenges before they are FDA approved and reach the market, there are a number of

112 efficacy of auranofin (rheumatoid arthritis FDA-approved drug) in a CDI mouse model and establish an

113 nds with oncological annotations, as well as FDA-approved drugs, and identified 155 that reduced the

114 of problems, including the lack of available FDA-approved/cleared tests, limited uptake of internatio

115 primer sets and four commercially available, FDA emergency use authorized assays for SARS-CoV-2 (Ceph

116 very low ultrasound pressures (20-fold below FDA safety limits for diagnostic imaging).

117 rd of all new molecular entities approved by FDA.

118 te was mcr positive) and 12 mcr-positive CDC-FDA Antibiotic Resistance (AR) Isolate Bank isolates for

119 n, which ultimately supported first-in-class FDA clearance for extragenital assays.

120 Currently, clinical FDA and European Committee on Antimicrobial Susceptibili

121 al and Laboratory Standards Institute (CLSI)-FDA and European Committee on Antimicrobial Susceptibili

122 reted according to the investigational CLSI, FDA, and EUCAST breakpoints, and results were compared.

123 cefiderocol ASTs are interpreted using CLSI, FDA, and EUCAST breakpoints.

124 Applying CLSI-FDA breakpoints, categorical agreement (CA) reached 93.0

125 votal clinical trials linked to contemporary FDA-approved cancer drugs, reported CVD event rates trai

126 Current FDA approved CKIs are also highlighted, in addition to a

127 a single dose of fluconazole 150 mg (current FDA-approved dose to treat acute VVC).

128 wer limit of quantification (LOQ) of current FDA-cleared plasma HIV-1 RNA assays (20 to 40 copies/ml)

129 tion, a method embodied by the seven current FDA-approved antibody-drug conjugates (ADC).

130 Most of the current FDA and EMA approved therapeutic monoclonal antibodies (

131 Yet, even with the current FDA approval for two FLT3 inhibitors, these modalities w

132 ions, influenza viruses resistant to current FDA antivirals have been reported and continue to emerge

133 It is currently FDA approved for essential tremor and tremor dominant Pa

134 The only currently FDA-approved rexinoid, bexarotene, is ineffective as a s

135 Additionally, two currently FDA approved drugs, afatinib and palbociclib (EGFR and C

136 nctionalization of a natural product-derived FDA-approved therapeutic.

137 of experiments (DOEs) using three different FDA-approved human inhaler devices followed by interacti

138 US Securities and Exchange Commission, Drugs@FDA database, and ClinicalTrials.gov, alongside publishe

139 From the Drugs@FDA, clinicaltrials.gov, MEDLINE, and publicly available

140 er of PEGylated therapeutics that are either FDA-approved or in clinical development, methods that su

141 n points that can be addressed with existing FDA-approved pharmaceuticals.

142 There were few FDA approvals prior to 2016, mostly of drugs that eventu

143 evaluate how far away we are from the first FDA-approved drug therapy for mitochondrial disease.

144 Overall, the database is insufficient for FDA approval of any psychedelic compound for routine cli

145 Currently, all four FDA-approved HDAC-targeting drugs are nonselective, pan-

146 n of the off-target kinase landscape of four FDA-approved PARP drugs.

147 Adverse event information available from FDA product labels and scientific literature for drugs t

148 stat is the first epigenetic therapy to gain FDA approval in a solid tumor.

149 ical trial and another that recently garnerd FDA-approval, indicating a bright future for targeted sm

150 a high-throughput drug screen, we identified FDA-approved drugs that can suppress HIV-1 reactivation

151 a drug repositioning strategy to investigate FDA-approved gold-containing drugs against N. gonorrhoea

152 ose) polymerase (PARP) inhibitor olaparib is FDA approved for the treatment of BRCA-mutated breast, o

153 Remdesivir (RDV) is FDA approved for COVID-19, but not recommended for patie

154 eers (3/10) had PTR results below 75%, a key FDA acceptability criterion for stored donor RBCs.

155 Veritor met FDA emergency use authorization (EUA) acceptance criteri

156 d 92 (84%) achieved HIV-1 RNA <50 copies/mL (FDA snapshot).

157 Moreover, new FDA regulatory paradigms have enabled the rapid review a

158 There are no FDA-approved antivirals or vaccines for any coronavirus,

159 al use as a bioterrorism agent, there are no FDA-approved antivirals or vaccines for treatment or pre

160 Currently, there are no FDA-approved vaccines or therapeutics available to comba

161 Currently, there are no FDA-approved vaccines to combat this virus.

162 There are currently no FDA-approved medications to reduce cocaine relapse.

163 Currently, no FDA-approved therapies exist for NPC and the mechanisms

164 e treatment of cuSCC, which currently has no FDA-approved targeted therapies.See related commentary b

165 been investigated, but currently there is no FDA-approved drug that can alleviate disease symptoms or

166 Currently, there is no FDA-approved medication to treat this devastating diseas

167 gy for VS, a condition for which there is no FDA-approved pharmacotherapy.

168 Unfortunately, there is no FDA-approved treatment specific for chlamydial infection

169 Despite the wide prevalence, no FDA-approved disease-modifying drugs exist.

170 Despite intense research, there is still no FDA-approved medication to treat cocaine use disorder (C

171 o hearing aids and cochlear implants with no FDA-approved drugs.

172 a significant public health concern with no FDA-approved treatment.

173 The absence of FDA oversight of serologic tests is concerning given tha

174 urposing the novel therapeutic properties of FDA-approved drugs.

175 Repurposing of FDA-approved drugs that can eradicate the CSC subcompart

176 e was previously identified from a screen of FDA-approved drugs as a potent EBOV viral entry inhibito

177 s of three steps: computational screening of FDA-approved drugs; in vitro and/or in vivo assays; and

178 known as 'maturation' that is the target of FDA-approved antiretroviral drugs.

179 to supportive therapies and off-label use of FDA-approved drugs.

180 l malignancies and underscore the utility of FDA-approved Trk inhibitors for patients with aggressive

181 Women with identified dMMR should be offered FDA-approved treatment based on these results.

182 While there is one FDA-approved therapy, it is associated with potential ad

183 At this time, only one FDA-approved anti-SARS-CoV-2 antiviral drug, remdesivir,

184 n (rHuEPO) therapeutic protein products; one FDA-licensed rHuEPO originator biological product, three

185 CellSearch, the only FDA-approved method for the CTC-based cancer prognosis,

186 tis worldwide; yet currently, no vaccines or FDA-approved antiviral drugs are available to counter th

187 entrectinib and pembrolizumab have received FDA approval for the treatment of patients with tumours

188 selective inhibitors, including the recently FDA-approved alpelisib.

189 AM-in-CDM approach will be used to repurpose FDA-approved drugs for various new therapeutic indicatio

190 To repurpose FDA-approved drugs potentially toxic for CSCs, we focuse

191 Two repurposed FDA-approved VCP inhibitors abrogated VCP-mediated repre

192 effective vaccine is available, repurposing FDA approved drugs could significantly shorten the time

193 ule, Voxelotor was recently approved by U.S. FDA to treat SCD.

194 ys (IGRAs) to receive approval from the U.S. FDA, replacing its predecessor, QuantiFERON-TB Gold In-T

195 The only currently U.S. FDA-approved vaccine to prevent anthrax in humans is ant

196 However, several FDA approvals have occurred in the past 4 years, restori

197 For instance, there are now several FDA-approved medications that target the sequelae of abe

198 ber of pneumonic cases of disease, we sought FDA approval of antimicrobials for treatment under the A

199 latter-phase (II and III) trials supporting FDA approval of anticancer drugs from 1998 to 2018 were

200 bolite analysis in GBM models, we found that FDA-approved global (panobinostat, vorinostat) and selec

201 We tested the hypothesis that FDA-approved BTK inhibitors (BTKis) would prevent IgE-me

202 We also provide proof-of-principle that FDA-approved inhibitors with activity against MEKK2 can

203 The FDA AERS database contained 27,123 EGFR-TKI-associated A

204 The FDA approvals of Rhopressa, Vyzulta, and Roclatan for gl

205 The FDA approved 355 new drugs and biologics over the study

206 The FDA approved the immune checkpoint inhibitors pembrolizu

207 The FDA funding needed to implement and manage these program

208 The FDA Green Book is a list of all drug products that have

209 The FDA has increasingly accepted less data and more surroga

210 The FDA-approved DNA hypomethylating agents (DHAs) like 5-az

211 The FDA-approved drug rapamycin slows aging and extends life

212 The FDA-approved prophylactic antimalarial drug atovaquone (

213 The probability of a VN titer of >=160, the FDA-recommended level for convalescent plasma used for C

214 Between 1997 and 2018, the FDA approved opioids on the basis of pivotal trials of s

215 ption across eGFR level before and after the FDA label change.

216 Although the FDA black box warning states that Cryptococcus spp. do n

217 into the biology of antidepressants and the FDA approval of its s-isomer, Esketamine (Spravato), the

218 hrane Database of Systematic Reviews and the FDA drug database from inception until Nov 22, 2019 for

219 oved by the IRB committee of the NIH and the FDA.FUNDINGCenter for Clinical Research, NCI, NIH.

220 % for the A. baumannii complex when both the FDA and ISO criteria were followed.

221 The most common biomarker approved by the FDA (United States Food and Drug Administration) is the

222 h-throughput screen of drugs approved by the FDA (US Food and Drug Administration) and identified ent

223 ur PARP inhibitors have been approved by the FDA as cancer therapeutics, yet a precise mechanistic ra

224 receptor 2 (HER2) inhibitor approved by the FDA for HER2-positive breast cancer treatment; however,

225 ral antidepressant, has been approved by the FDA for treating treatment-resistant major depressive di

226 drug products that have been approved by the FDA for use in veterinary medicine.

227 ntifying antimicrobial drugs approved by the FDA from 2007-2016 that would likely have qualified for

228 Romosozumab, approved by the FDA in 2019, is a humanized sclerostin-neutralizing anti

229 n in 2018 and triclabendazole in 2019 by the FDA marked an important moment in the fight against dise

230 rings in small molecule APIs approved by the FDA through 2019 and show that only a few substitution p

231 s granted emergency use authorization by the FDA using nasopharyngeal swabs from symptomatic patients

232 opathy examination de novo authorized by the FDA, after a preregistered clinical trial.

233 oclonal antibody therapeutic approved by the FDA, binds to PD-1 and efficiently blocks its pathways.

234 ng on new therapeutic agents approved by the FDA, capitalized at a real cost of capital rate (the req

235 ng-term increase of neuronal activity by the FDA-approved drug 4-aminopyridine (4-AP) rescues the num

236 inhibition of TRPM7 channel activity by the FDA-approved drug FTY720 increased the sensitivity of T

237 beta MAPK-mediated activation of p300 by the FDA-approved kinase inhibitor, nilotinib, ameliorates ca

238 s of magnitude more than that induced by the FDA-approved lipid nanoparticle material MC3 in vaccinat

239 allenges of gaining clinical approval by the FDA-in particular, with regards to biological, mechanica

240 ll safety data received and processed by the FDA.

241 Memorial Sloan Kettering Cancer Center, the FDA, and the National Marrow Donor Program.FUNDINGThis w

242 ing MAO-A with phenelzine or clorgyline, the FDA-approved drugs for antidepression, resensitize the E

243 Here, we explore the FDA-approved drug quinidine as a P-gp inhibitor.

244 dent has been previously established for the FDA-approved bispecific T cell engager, blinatumomab, fo

245 lance system, the WHO VigiBase, and from the FDA Adverse Event Reporting System), 87 from Boehringer

246 ent reports for these KIs, obtained from the FDA Adverse Event Reporting System, are used to compute

247 98 from the literature search, two from the FDA homepage search, ten from the Risk Evaluation and Mi

248 e emergency use authorization (EUA) from the FDA.

249 Here, we investigate how the FDA-approved antihypertensive drug, guanabenz, which has

250 phase 2 dose (RP2D, primary outcome) is the FDA/EMEA approved dose of gemcitabine-nab-paclitaxel alo

251 NMDAR antagonist NitroSynapsin, but not the FDA-approved drug memantine, abrogated this hyperactivit

252 vitro and in vivo anti-tumor effects of the FDA-approved ETAR antagonist, Ambrisentan, which is curr

253 ighlighted in the efficient synthesis of the FDA-approved therapeutic lipopeptide tesamorelin and pal

254 tes from a multicenter clinical trial of the FDA-cleared Unyvero lower respiratory tract infection (L

255 Overall, the FDA found that the model label was adequate for use in t

256 We repurposed the FDA-approved bile acid sequestrant cholestyramine, which

257 To combat VRE, we have repurposed the FDA-approved carbonic anhydrase drug acetazolamide to de

258 These data indicate that repurposing the FDA-approved leukemia drug, nilotinib, may be effective

259 nvestigated the potential of repurposing the FDA-approved spironolactone (SP), as one such drug.

260 ical complete response rates, supporting the FDA approval.

261 is gap in knowledge and demonstrate that the FDA-approved broad-spectrum anti-infective drug nitazoxa

262 f C. difficile in vitro, suggesting that the FDA-approved formulation of UDCA, known as ursodiol, may

263 We now show that the FDA-approved histone deacetylase inhibitor (HDACi) valpr

264 hypothesis, we make the prediction that the FDA-approved molecule, icatibant, might be able to inter

265 Regulatory endorsement through the FDA Biomarker Qualification Program encourages the use o

266 from six recent CABP trials submitted to the FDA (n=4,645 participants) to evaluate concordance betwe

267 egies (2008-2018); and user fees paid to the FDA by industry (1993-2018).

268 free sharing of information relating to the FDA drug registration process, it will prove less daunti

269 reover, data from a phase I study led to the FDA granting breakthrough therapy designation to enfortu

270 for the sensitization of cancer cells to the FDA-approved topoisomerase inhibitors topotecan and irin

271 tinib, osimertinib) by data mining using the FDA adverse event reporting system (AERS) database, and

272 Using the FDA snapshot algorithm, 84/93 (90.3%) participants in th

273 ber of antibacterial INDs initiated with the FDA from 2010-2019 was lower than any of the previous th

274 1%] with the EMA, seven of 16 [44%] with the FDA, none of ten for the PMDA).

275 gistically improved by combining it with the FDA-approved anti-malarial, chloroquine, a known lysosom

276 maged cells, the cells were treated with the FDA-approved poloxamer 188 (P188).

277 ronal activity by chronic treatment with the FDA-approved potassium channel blocker 4-aminopyridine (

278 ive effects on HNSCC cells compared with the FDA-approved translation inhibitor omacetaxine mepesucci

279 rticipates in the inhibition exerted by this FDA-approved drug.

280 Currently, there are only three FDA-approved drugs that inhibit human immunodeficiency v

281 vaccines advancing from launch of phase 2 to FDA licensure within 10 years.

282 ne means of treating SMA and recently led to FDA approval of an intrathecally delivered SMN-enhancing

283 ectively cover the disease module similar to FDA-approved drug combinations and could potentially sug

284 These data were submitted to FDA and plague indications were approved.

285 also predicted highly divergent MoAs for two FDA-approved antihistamines.

286 Importantly, we identified two FDA-approved drugs able to ameliorate these phenotypes.

287 Through screening, two FDA-approved drugs, Oxytetracycline and Sunitinib, were

288 inistration of nicotine and varenicline, two FDA-approved smoking cessation aids, during abstinence),

289 n the intensive care unit, as part of the US FDA expanded access program for COVID-19 convalescent pl

290 pproved for use in various cancers by the US FDA.

291 yanine green (ICG) is the most commonly used FDA-approved agent for clinical optical imaging, adminis

292 Results were interpreted using FDA (prior to 28 September 2020 update), EUCAST, and inv

293 ally enhancing RAI therapy in patients using FDA-approved drugs.

294 subsequent labels of all vaccines that were FDA-approved between 1 January 1996 and 31 December 2015

295 as 96.4% and 96.6% for Enterobacterales when FDA and ISO 20776-2 criteria, respectively, were followe

296 While FDA approved for conditions such as Parkinson's disease,

297 ategies for SARS-CoV-2 serologic assays with FDA EUA are provided, as are insights into assay limitat

298 parative analysis of known SA complexes with FDA-approved drugs clearly shows that multiple medicatio

299 nes; of these, 54 are known to interact with FDA-approved drugs.

300 We demonstrate that treatment with FDA-approved HCQ leads to decreased muscle fibrosis and